Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China

AimTo determine the pharmacoeconomics of empagliflozin for the treatment of heart failure (HF) with reduced ejection fraction in China and to provide evidence-based reference for clinical rational drug selection and medical decision-making.Research design and methodsWe used the Markov model to evalu...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Haiqiang Sang, Yiming Wan, Zhenzhou Ma, Shengye Zhang, Qiuping Zhao
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2022-11-01
Edice:	Frontiers in Cardiovascular Medicine
Témata:	cost-benefit analysis empagliflozin heart failure with reduced ejection fraction pharmacoeconomics medical decision-making
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fcvm.2022.1022020/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!